An Interview With...
Mojgan Moshgbar Director, Team Leader, Advanced Manufacturing Technology
Global Technology Services, PGS Pfizer
» What is Intellicentic™?
Intellicentic™ refers to a broad mix of consulting services and advanced platform technologies developed in concert with key pharmaceutical manufacturing suppliers, service providers and Pfizer Incorporated’s experience and broad manufacturing knowledge. These platforms are based on technologies developed for Pfizer internal use. The main focus of the Intellicentic solutions is on de-risking the processes, reducing variation, improving yield, costs, cycle time and overall agility and predictability of manufacturing processes.
What are the key benefits of Intellicentic™ for Pfizer and the pharmaceutical industry?
Pfizer’s primary interest in Intellicentic™ is to promote technology uptake in the industry. A broader uptake of these technologies will accelerate regulatory awareness and acceptance that will in turn benefit Pfizer and eventually the patients. Development of Intellicentic platforms has required significant investment over a seven-year period, and a critical mass of highly specialized subject matter experts in key areas of science and technology: advanced integrated PATs, applied multivariate analysis, advanced process control and real-time optimization. Open access to these mature and proven technologies will provide significant benefit to other Pharma companies without the need to replicate such an undertaking.
Are Intellicentic™ Platforms affordable for smaller companies?
The value proposition of Intellicentic is based on impactful and measurable process improvement and short payback periods (in many cases less than two years). Our vision is to make transformational
110 | | September/October 2013 - 15TH ANNIVERSARY ISSUE
technologies more accessible to the entire industry and create a new technical benchmark to fuel future growth.
What is Intellicentic’s business model?
Inspired by open innovation principles, the Intellicentic model is based on a non-competitive collaboration between Pfizer and a number of technology providers. Currently, the partnership includes Perceptive Engineering, Ltd. (
www.perceptiveapc.com), Stottler Henke Associates, Inc. (
www.StottlerHenke.com), Middleton Research (www.
middletonresearch.com), Metrohm USA, Inc. (
www.metrohmusa. com), and Federal Equipment Company (
www.fedequip.com) who will represent Pfizer in any customer facing interaction. These companies were selected based on the maturity and complementary strength of their products and services, and our long-standing experience with each of them. We are currently considering a few other companies, including a number of top biopharmaceutical equipment manufacturers, who could offer additional synergy to this model.
What are the key benefits for your Intellicentic partners?
Intellicentic™ provides an additional marketing avenue to our partners and an extension to their existing product portfolio, without the need for any investment to develop these capabilities in-house. The collaboration between partners will fuel open innovation and is a true win-win for all concerned including future adopters in industry.
Walk us through a specific example of how this technology is applied.
One of the Intellicentic platforms is designed to reduce the time and efforts needed to optimize crystallization processes from
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156